StockData
Kiora Pharmaceuticals Inc logo

Kiora Pharmaceuticals Inc (KPRX) stock

KPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as KPHMW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$0.93−0.05 (-5.30%)

Close on Nov 17, 2026Market cap $4.11MP/E –Yield –

Kiora Pharmaceuticals ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Kiora Pharmaceuticals's ebitda for the twelve months ending Jun 30, 2026 was -$12.79M. For fiscal 2025 it was -$12.81M, down 382.7% from the year before. The highest annual figure on record is $4.53M in fiscal 2024.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$12.81M-382.7%
FY2024Dec 31, 2024$4.53M–
FY2023Dec 31, 2023-$12.54M–
FY2022Dec 31, 2022-$12.27M–
FY2021Dec 31, 2021-$14.19M–
FY2020Dec 31, 2020-$6.84M–
FY2018Dec 31, 2018-$10.81M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.20M–
Q1 FY2026Mar 31, 2026-$2.50M–
Q4 FY2025Dec 31, 2025-$7.30M–
Q3 FY2025Sep 30, 2025-$783.89K–
Q2 FY2025Jun 30, 2025-$2.39M–
Q1 FY2025Mar 31, 2025-$2.33M-117.6%
Q4 FY2024Dec 31, 2024-$2.56M–
Q3 FY2024Sep 30, 2024-$3.60M–
Q2 FY2024Jun 30, 2024-$2.54M–
Q1 FY2024Mar 31, 2024$13.23M–
Q4 FY2023Dec 31, 2023-$2.11M–
Q3 FY2023Sep 30, 2023-$5.91M–
Q2 FY2023Jun 30, 2023-$2.61M–
Q1 FY2023Mar 31, 2023-$1.91M–
Q4 FY2022Dec 31, 2022-$2.62M–
Q3 FY2022Sep 30, 2022-$3.69M–
Q2 FY2022Jun 30, 2022-$2.39M–
Q1 FY2022Mar 31, 2022-$3.56M–
Q4 FY2021Dec 31, 2021-$6.36M–
Q3 FY2021Sep 30, 2021-$3.02M–
Q2 FY2021Jun 30, 2021-$2.81M–
Q1 FY2021Mar 31, 2021-$2.00M–
Q4 FY2020Dec 31, 2020-$1.16M–
Q3 FY2020Sep 30, 2020-$2.00M–
Q2 FY2020Jun 30, 2020-$1.71M-303.5%
Q1 FY2020Mar 31, 2020-$1.96M–
Q3 FY2019Sep 30, 2019-$3.44M–
Q2 FY2019Jun 30, 2019-$1.86M–
Q1 FY2019Mar 31, 2019$841.56K–
Q4 FY2018Dec 31, 2018-$2.48M–
Q3 FY2018Sep 30, 2018-$3.17M–
Q2 FY2018Jun 30, 2018-$2.79M–
Q1 FY2018Mar 31, 2018-$2.37M–
Q3 FY2017Sep 30, 2017-$4.14M–
Q2 FY2017Jun 30, 2017-$3.32M–
Q1 FY2017Mar 31, 2017-$2.92M–
Q3 FY2016Sep 30, 2016-$3.38M–

More Kiora Pharmaceuticals figures

See a number that looks wrong?